L-name-induced hypertension does not completely reproduce the hemodynamic pattern of the hypertensive-diabetic cardiomyopathy in rats

International Journal of Atherosclerosis

Volumn 3, Issue 1, 2008, Pages 44-49

  Gazzoto, Ademir ^a   Sabha, Maricene ^a   Frigato, Valéria ^a   Ferreira Melo, Sílvia Elaine ^a   Bignotto, Letícia Maria ^a   Lacchini, Riccardo ^a   Tanus Santos, José Eduardo ^b   Moreno Jr , Heitor ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cardiomyopathy; Hemodynamics; Hypertension

Indexed keywords

N(G) NITROARGININE METHYL ESTER; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CLAMP; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; CARDIOMYOPATHY; CARDIOVASCULAR FUNCTION; CONTROLLED STUDY; DISEASE MODEL; HEART LEFT VENTRICLE DP-DT; HEART OUTPUT; HEART RATE; HEMODYNAMIC PARAMETERS; HISTOPATHOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; ISOLATED HEART; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; RAT; RENOVASCULAR HYPERTENSION; REPRODUCIBILITY; STREPTOZOCIN DIABETES; VASCULAR RESISTANCE;

EID: 77953387284     PISSN: 18092942     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991 Jun;43(2):109-42.
2. Arnal JF, el Amrani AI, Chatellier G, Menard J, Michel JB. Cardiac weight in hypertension induced by nitric oxide synthase blockade. Hypertension. 1993 Sep;22(3):380-7.
3. Moreno Júnior H, Metze K, Zatz R, De Nucci G. Chronic nitric oxide blockade causes cardiac ischaemia but not cardiac hypertrophy: An experiment of four weeks in rats. Verh Dtsch Ges Path. 1994;78:459.
4. Pechánová O, Bernátová I. Effect of long-term NO synthase inhibition on cyclic nucleotide content in rat tissues. Physiol Res. 1996; 45(4):305-9.
5. Babál P, Pechánová O, Bernátová I, Stvrtina S. Chronic inhibition of NO synthesis produces myocardial fibrosis and arterial media hyperplasia. Histol Histopathol. 1997 Jul; 12(3):623-9.
6. Bernátová I, Pechánová O, Kristek F. Mechanism of structural remodelling of the rat aorta during long-term NG-nitro-L-arginine methyl ester treatment. Jpn J Pharmacol. 1999 Sep; 81(1):99-106.
7. Pechánová O, Bernátová I, Babál P. Structural alterations in the heart after long-term L-NAME and D-NAME treatment. Gen Physiol Biophys. 1999 Dec;18 Suppl 1:6-9.
8. Lip GY, Felmeden DC, Li-Saw-Hee FL, Beevers DG. Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'? Eur Heart J. 2000 Oct;21(20):1653-65.
9. Grossman E, Messerli FH. Diabetic and hypertensive heart disease. Ann Intern Med. 1996 Aug 15;125(4):304-10.
10. Sowers JR, Epstein M, Frohlich ED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001 Apr;37(4):1053-9.
11. Factor SM, Minase T, Cho S, Capasso JM, Sonnenblick EH. Coronary microvascular abnormalities in the hypertensive-diabetic rat. A primary cause of cardiomyopathy? Am J Pathol. 1984 Jul;116(1):9-20.
12. Mathis DR, Liu SS, Rodrigues BB, McNeill JH. Effect of hypertension on the development of diabetic cardiomyopathy. Can J Physiol Pharmacol. 2000 Oct;78(10):791-8.
13. Kojda G, Harrison D. Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res. 1999 Aug 15;43(3):562-71.
14. Bayraktutan U, Yang ZK, Shah AM. Selective dysregulation of nitric oxide synthase type 3 in cardiac myocytes but not coronary microvascular endothelial cells of spontaneously hypertensive rat. Cardiovasc Res. 1998 Jun;38(3):719-26.
15. Hink U, Li H, Mollnau H, Oelze M, Matheis E, Hartmann M, Skatchkov M, Thaiss F, Stahl RA, Warnholtz A, Meinertz T, Griendling K, Harrison DG, Forstermann U, Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ Res. 2001 Feb 2;88(2):E14-22.
16. Sampaio RC, Tanus-Santos JE, Melo SE, Hyslop S, Franchini KG, Luca IM, Moreno H Jr. Hypertension plus diabetes mimics the cardiomyopathy induced by nitric oxide inhibition in rats. Chest. 2002 Oct;122(4):1412-20.
17. Goldblatt H, Lynch J, Hanzal RF, Summerville WW. Studies on experimental hypertension. The production of persistent elevation of systolic blood pressure by means of renal ischemia. J Exp Med. 1934;59:347-79.
18. Moreno H Jr, Metze K, Antunes E, Zatz R, De Nucci G. Chronic nitric oxide inhibition as a model of hypertensive heart muscle disease. Basic Res Cardiol. 1996 May-Jun;91(3):248-55.
19. Zatz R. A low cost tail-cuff method for the estimation of mean arterial pressure in conscious rats. Lab Anim Sci. 1990 Mar;40(2):198-201.
20. Langendorff. Untersuchungen am überlebenden Säugethierherzen. Pflügers Arch Ges Physiol. 1895;291-332.
21. Sigmon D, Beierwaltes WH. Influence of nitric oxide in the chronic phase of two-kidney, one clip renovascular hypertension. Hypertension. 1998 Feb;31(2):649-56.
22. Zhong N, Zhang Y, Zhu HF, Wang JC, Fang QZ, Zhou ZN. Myocardial capillary angiogenesis and coronary flow in ischemia tolerance rat by adaptation to intermittent high altitude hypoxia. Acta Pharmacol Sin. 2002 Apr;23(4):305-10.
23. Fredersdorf S, Thumann C, Ulucan C, Griese DP, Luchner A, Riegger GA, Kromer EP, Weil J. Myocardial hypertrophy and enhanced left ventricular contractility in Zucker diabetic fatty rats. Cardiovasc Pathol. 2004 Jan-Feb;13(1):11-9.
24. Sun Y, Zhang J, Lu L, Bedigian MP, Robinson AD, Weber KT. Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart. J Lab Clin Med. 2004 Jan; 143(1):41-51.
25. Matsubara BB, Matsubara LS, Zornoff LA, Franco M, Janicki JS. Left ventricular adaptation to chronic pressure overload induced by inhibition of nitric oxide synthase in rats. Basic Res Cardiol. 1998 Jun; 93(3):173-81.
26. Pessanha MG, Mandarim-de-Lacerda CA. Influence of the chronic nitric oxide synthesis inhibition on cardiomyocytes number. Virchows Arch. 2000 Dec; 437(6):667-74.
27. Maejima Y, Adachi S, Ito H, Nobori K, Tamamori-Adachi M, Isobe M. Nitric oxide inhibits ischemia/reperfusion-induced myocardial apoptosis by modulating cyclin A-associated kinase activity. Cardiovasc Res. 2003 Aug 1;59(2):308-20.
28. Pechánová O, Bernátová I, Pelouch V, Babál P. L-NAME-induced protein remodeling and fibrosis in the rat heart. Physiol Res. 1999; 48(5):353-62.
29. Stockklauser-Färber K, Ballhausen T, Laufer A, Rösen P. Influence of diabetes on cardiac nitric oxide synthase expression and activity. Biochim Biophys Acta. 2000 Dec 15;1535(1):10-20.
30. Bojunga J, Dresar-Mayert B, Usadel KH, Kusterer K, Zeuzem S. Antioxidative treatment reverses imbalances of nitric oxide synthase isoform expression and attenuates tissue-cGMP activation in diabetic rats. Biochem Biophys Res Commun. 2004 Apr 9;316(3):771-80.
31. Moshage H. Nitric oxide determinations: much ado about NO.-thing? Clin Chem. 1997 Apr;43(4):553-6.
32. Jungersten L, Edlund A, Petersson AS, Wennmalm A. Plasma nitrate as an index of nitric oxide formation in man: analyses of kinetics and confounding factors. Clin Physiol. 1996 Jul;16(4):369-79.
33. Kobayashi T, Kamata K. Effect of chronic insulin treatment on NO production and endothelium-dependent relaxation in aortae from established STZ-induced diabetic rats. Atherosclerosis. 2001 Apr;155(2):313-20.
34. Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res. 1999 Aug 15;43(3):521-31.
35. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000 Nov 10;87(10): 840-4.
36. Koo JR, Vaziri ND. Effects of diabetes, insulin and antioxidants on NO synthase abundance and NO interaction with reactive oxygen species. Kidney Int. 2003 Jan;63(1):195-201.